Management pivoting a $300 billion company as quickly as it has is nothing short of remarkable.
The company is grappling with losing Humira's patent protection in 2023.
These companies offer above-average income streams that should continue rising.
The big drugmaker went on a holiday shopping spree.
Here's what's attracting lucrative buyout offers from big pharmaceutical companies these days.
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cerevel Therapeutics Holdings, Inc. ("Cerevel" or the "Company") (NASDAQ: CERE)....
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cerevel Therapeutics Holdings, Inc. ("Cerevel" or the "Company") (NASDAQ: CERE)....
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cerevel Therapeutics Holdings, Inc. ("Cerevel" or the "Company") (NASDAQ: CERE)....
The company reported second-quarter earnings.
/PRNewswire/ -- Quantiphi, an AI-first digital engineering company, today announced that it has entered into a collaboration with Cerevel Therapeutics (Nasdaq:...